Genmab | Des Atouts



Assets Changement Date
Agios Pharmaceuticals USD 1.66B 128.6M 2024-12
Almirall EUR 2.32B 14.19M 2024-06
Amarin USD 750.62M 49.24M 2024-09
Amgen USD 91.84B 956M 2024-12
AstraZeneca USD 104.04B 887M 2024-12
Bayer EUR 110.85B 3.9B 2024-12
BioMarin Pharmaceutical USD 6.99B 137.74M 2024-12
Demant DKK 32.45B 60M 2024-12
Exelixis USD 2.95B 12.59M 2025-01
Fresenius Medical Care EUR 33.57B 1.06B 2024-12
Galapagos EUR 4.14B 36.48M 2024-12
Genmab DKK 45.81B 6.15B 2024-12
GlaxoSmithKline GBP 59.46B 1.41B 2024-12
GN Store Nord DKK 21.68B 7.9B 2024-12
GRIFOLS EUR 21.41B 1.12B 2024-12
Hikma Pharmaceutical USD 4.85B 167M 2024-06
Insmed USD 2.03B 27.74M 2024-12
Lonza CHF 19.73B 1.85B 2024-12
Merck EUR 51.57B 1.42B 2024-12
Novartis USD 102.25B 1.28B 2024-12
Regeneron Pharmaceuticals USD 37.76B 317.5M 2024-12
Roche Holding CHF 101.8B 6.02B 2024-12
Sanofi 129.76B 3.29B 2024-06
UCB EUR 17.35B 1.72B 2024-12



Genmab Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Apr 2025.